Uncovering the Therapeutic Target and Molecular Mechanism of Upadacitinib on Sjogren’s Syndrome
Objective: Upadacitinib, a selective Janus associated kinase 1 (JAK-1) inhibitor, can be prescribed particularly for the clinical treatment with Crohn’s disease or rheumatoid arthritis. It is clinically observed that upadacitinib has been found with potential therapeutic effectiveness on Sjogren’s s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-10-01
|
| Series: | Biomedical Engineering and Computational Biology |
| Online Access: | https://doi.org/10.1177/11795972241293519 |